India rejects patents on Tamiflu
This article was originally published in Scrip
Executive Summary
India has rejected Gilead Sciences' patent application for its antiviral Tamiflu (oseltamivir) on multiple grounds, including obviousness. Gilead's application had been opposed by Cipla and another domestic firm, Intermed.